JAK2-V617F Mutation In Polycythemia Vera Of Iran
Evaluation of patients with myeloproliferative disorders Genetic mutation JAK2-V617F in polycythemia vera in the TABRIZ
Versandkostenfrei!
Versandfertig in 1-2 Wochen
52,99 €
inkl. MwSt.
PAYBACK Punkte
26 °P sammeln!
Today the hematological infectious diseases are very important. Dangerous and life-threatening human diseases, such as polycythemia is also very important and must do more research Catch. Unfortunately routes now there is no cure for the disease, polycythemia, and every year the number of deaths the disease will increase. Genetic studies in the future we hope to be able to cure this disease is very dangerous.Chronic myeloproliferative disorders (MPDs) are a heterogeneous group of diseases in which a clonal disorder of hematopoietic stem cells leads to an increase in the level of production in ...
Today the hematological infectious diseases are very important. Dangerous and life-threatening human diseases, such as polycythemia is also very important and must do more research Catch. Unfortunately routes now there is no cure for the disease, polycythemia, and every year the number of deaths the disease will increase. Genetic studies in the future we hope to be able to cure this disease is very dangerous.Chronic myeloproliferative disorders (MPDs) are a heterogeneous group of diseases in which a clonal disorder of hematopoietic stem cells leads to an increase in the level of production in one or more of the blood cell. JAK2V617F recently acquired mutations in many patients with chronic myeloproliferative disorders (MPDs) is described by changing G to T mutation at nucleotide 1849 in exon 12 of the JAK2 gene is located on chromosome 9 identified, which leads to substitution of the amino acid phenylalanine instead of valine at position 617 of the protein JAK2 Grdd.hdf of this study to evaluate the frequency of these mutations in patients with MPDs was.
Andere Kunden interessierten sich für
